Phase 2 N=29 Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT
Multiple Myeloma
Primary: Maximum Tolerated Dose of Thalidomide — 1000; 1000 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=91 Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Primary: Phase A: Change From Baseline in Spot Urine Osmolality (Pre-morning Dose) — 635; 646; -386; -93 milliosmoles per kilogram (mOsm/kg)
Phase 3 N=138 Long-Acting Growth Hormone in Children Compared to Daily rhGH
Growth Disorders
Primary: Annual Height Velocity — 9.43; 10.70 cm/year
Phase 2 N=127 Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
Hepatocellular Carcinoma · Liver Metastases · Cutaneous or Subcutaneous Lymph Node
Primary: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) — 2; 0; 1; 0 Participants
Phase 1 N=40 MW151-101: First-in-human Study of MW151
Drug Toxicity
Primary: Percentage of Participants Experiencing Drug-related Serious Adverse Events. — 0; 0; 0; 0 percentage of participants
N/A N=22 Cytosponge and Dietary Therapy in EoE
Eosinophilic Esophagitis
Primary: Histological Remission by Sponge Cytology — 13 Participants
N/A N=26 Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder I
Primary: Change (Δ) in Accuracy of Time Interval Discrimination Pre- and Post-TMS — .503; .521; .456; .479 accuracy (proportion correct) — p=0.51
Phase 2 N=600 Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
SARS-CoV-2
Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 95; 69; 72; 65 Participants
N/A N=58 Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use
Cannabis Use
Primary: Brief Intervention Acceptability — 23; 1; 0 Participants
Phase 2 N=38 Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529
Hypertension, Pulmonary
Primary: Number of Participants With Non-serious Treatment-emergent Adverse Events (Non-STEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) — 3; 13; 5; 10 Participants
Phase 3 N=1,072 A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
Chronic Spontaneous Urticaria
Primary: Mean Change From Baseline in UAS7 at Week 12 (Multiple Imputation) of Adult Subjects — -19.368; -19.330; -20.040; -11.366 Score — p=<.0001
Phase 4 N=22 A Rollover Study to Provide Continued Treatment With Eltrombopag
Thrombocytopaenia
Primary: Number of Participants With Adverse Events (AEs) — 7; 12; 6; 7 Participants
Phase 3 N=50 Regadenoson Real Time Perfusion Imaging Trial-Optison
Coronary Artery Disease · Myocardial Perfusion Abnormalities
Primary: Number of Participants With Coronary Stenosis — 50 Participants
N/A N=54 Clinical Investigation of the Visual Outcomes and Safety of a Trifocal Toric IOL in an Asian Population
Aphakia · Corneal Astigmatism
Primary: Mean Monocular Residual Manifest Cylinder for All Operative Eyes for All IOL Models Combined — 0.219; 0.198 diopter
Phase 2 N=36 Varenicline for Gait and Balance Impairment in Parkinson Disease
Parkinson Disease
Primary: Berg Balance Scale — 43.93; 41.14; 43.25; 45.13 score on a scale — p=0.05